The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 17, 2021
Filed:
Oct. 04, 2019
Applicant:
American Gene Technologies International Inc., Rockville, MD (US);
Inventors:
Charles David Pauza, Baltimore, MD (US);
Haishan Li, North Potomac, MD (US);
Tyler Lahusen, Frederick, MD (US);
Jeff Galvin, Rockville, MD (US);
Assignee:
American Gene Technologies International Inc., Rockland, MD (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C12N 15/113 (2010.01); A61K 48/00 (2006.01); C12N 15/86 (2006.01); A61K 35/17 (2015.01); A61K 39/21 (2006.01); A61P 31/18 (2006.01); A61K 45/06 (2006.01); A61K 39/12 (2006.01); C07K 14/715 (2006.01); A61K 31/7105 (2006.01); C12N 15/11 (2006.01); A61K 35/14 (2015.01); A61K 39/39 (2006.01); C12N 5/078 (2010.01); C12N 7/00 (2006.01); C12N 5/0783 (2010.01); A61K 35/15 (2015.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 31/7105 (2013.01); A61K 35/14 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 31/18 (2018.01); C07K 14/7158 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); C12N 15/111 (2013.01); C12N 15/1132 (2013.01); C12N 15/1138 (2013.01); C12N 15/86 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01); C12N 2330/51 (2013.01); C12N 2510/00 (2013.01); C12N 2710/24143 (2013.01); C12N 2740/15021 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15052 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16043 (2013.01);
Abstract
The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.